通脉口服液防治Ⅱ期糖尿病肾病的药效学分析.doc

通脉口服液防治Ⅱ期糖尿病肾病的药效学分析 目录 TOC \o 1-9 \h \z \u 目录 1 正文 1 文1：通脉口服液防治Ⅱ期糖尿病肾病的药效学分析 1 1 材料与方法 2 2 结果 4 3 讨论 6 文2：脉平片药效学分析 7 1 实验材料 7 2 方法与结果 8 3 讨论 10 参考文摘引言： 11 原创性声明（模板） 12 文章致谢（模板） 12 正文 通脉口服液防治Ⅱ期糖尿病肾病的药效学分析 文1：通脉口服液防治Ⅱ期糖尿病肾病的药效学分析 Abstract：Objective To investigate the effect of Tongmai oral liquid on the early diabetic nephropathy. Methods Diabetic nephropathy rats were induced by excision of the right kidney and a single intraperitoneal injection of streptozotocin (STZ). Forty male Wistar rats were pided randomly into 3 groups：Tongmai group， nephrotic model group， and normal group. At the end of the 8th week， the rats general states and some paramete such as kidney hypertrophy index， 24 h urine volume， blood glucose， 24 h urinary microalbumin (24 h UMA)， renal function [serum creatinine (Cr)， blood urea nitrogen (BUN)]， serum lipid， and the change of nephritic pathologic lesion were measured. Result Compared with the model group， general states in Tongmai group were improved， there was a coiderable increase on body weight (P＜). Compared with the model group， there was a significantly decrease (P＜) on the kidney hypertrophy index， blood glucose， BUN and Cr in Tongmai group. The pathologic lesion in kidney morphology were also ameliorated obviously. But there were no remarkable differences in the 24 h urine volume and serum lipid index. Conclusion Tongmai oral liquid can prevent and cure the Ⅱ period diabetic nephropathy by controlling blood glucose and improving renal hemodynamics。 Key words：Ⅱ period diabetic nephropathy；Tongmai oral liquid；pharmacodynamics；animal model 近年越来越重视的是糖尿病肾病的早期肾脏病变，此时，如给予适当的临床干预，可使肾小球高滤过率(GFR)下降，增大的肾脏逐渐恢复正常，从而使病变过程得到遏止甚至逆转。对糖尿病肾病早期诊断、早期治疗是研究糖尿病肾病的重点和突破口[1]。因此，我们开展了中医药干预糖尿病肾病Ⅰ～Ⅲ期的研究。 1 材料与方法 动物 健康Wistar雄性大鼠45只，体重(200±20)g，河北省实验动物中心提供，合格证号：DK0408-0034。 药物 通脉口服液，主要由黄芪、三七等药材组成，广东省中医院制剂室制备，批号071101。链脲佐菌素(STZ)，批号B69776， Sigma公司生产，使用时将STZ溶于新配制的 mol/L枸橼 酸缓冲液中(pH )，制成2%(20 mg/mL)的溶液。 主要试剂 血糖试剂盒，中生北控生物科技股份有